Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 3/20 | 0.44 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225101 | 0.79 | NTSR2 (0.56) | — | |
| SCHEMBL8225148 | 0.78 | NTSR2 (0.53) | BACE1 | |
| SCHEMBL8419008 | 0.78 | CALCRL (0.41) | CALCRLRAMP1BACE1BACE2KEAP1 | |
| SCHEMBL8418325 | 0.77 | NTSR2 (0.55) | BACE1 | |
| SCHEMBL8414624 | 0.75 | NTSR2 (0.51) | BACE1 | |
| SCHEMBL29680185 | 0.71 | CALCRL (0.55) | CALCRLRAMP1REN | |
| SCHEMBL30799423 | 0.70 | BACE1 (0.61) | BACE1BACE2PTPN1 | |
| SCHEMBL30799637 | 0.70 | BACE1 (0.64) | BACE1BACE2PTPN1 | |
| SCHEMBL30799786 | 0.69 | BACE1 (0.60) | BACE1BACE2PTPN1 | |
| SCHEMBL30799682 | 0.69 | BACE1 (0.58) | BACE1BACE2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | CALCRL 651/4885RAMP1 1186/4885BACE1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.